Document is current
Any future updates will be listed below
-
Authors
Won, Christine https://orcid.org/0000-0002-8568-8849
Bogan, Richard K.
Doghramji, Karl
Ojile, Joseph
Bujanover, Shay
Hyman, Danielle L.
Hewett, Kathleen A.
Thomas, Robert
-
Funding
Funding for this research was provided by:
Jazz Pharmaceuticals
- License Information
-
More Information
Article History
Received: 19 May 2021
Accepted: 25 March 2022
First Online: 25 May 2022
Declarations
:
: This study was approved by the New England Institutional Review Board (IRB Number: 120170306, Protocol Number: 1233110) and conducted in accordance with the amended Declaration of Helsinki. All recorded participants provided written informed consent.
: Not applicable.
: CW and KD are consultants for, and participate in research that is supported by, Jazz Pharmaceuticals. RKB is on the speakers’ bureau for Jazz Pharmaceuticals, advisory board and has participated in industry-sponsored research. JO is an employee of the Caduceus Corporation and the Clayton Sleep Institute, LLC; has received research funding from Fisher-Paykel, Jazz Pharmaceuticals, Respironics, and Teva; has served on the speakers’ bureaus for AstraZeneca, Boehringer Ingelheim, Merck, and Teva; and serves as a board member for the National Sleep Foundation. SB and DLH are former employees of Jazz Pharmaceuticals who, in the course of their employment, have received stock options exercisable for, and other stock awards of, ordinary shares of Jazz Pharmaceuticals PLC. KAH is an employee of Ogilvy Health and was a paid consultant to Jazz Pharmaceuticals in connection with performing this research and with the development of this publication. RT receives royalty payments from MyCardio, LLC for CG-based sleep and sleep apnea phenotyping software, has consulted for DeVilbiss-Drive for CPAP software development, and is a consultant for GLG Councils and Jazz Pharmaceuticals. He has a patent for a device regulating CO<sub>2</sub> for central/complex apnea treatment.
